MOTS - Motus GI Holdings, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.7400
+0.0800 (+4.82%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.6600
Open1.6900
Bid0.0000 x 2200
Ask0.0000 x 800
Day's Range1.6800 - 1.7700
52 Week Range1.6000 - 4.9900
Volume75,559
Avg. Volume75,859
Market Cap47.209M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.2130
Earnings DateNov 8, 2019 - Nov 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.10
Trade prices are not sourced from all markets
  • Business Wire

    Motus GI Announces First Commercial Placements of Pure-Vu® System as part of U.S. Market Launch

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today the first commercial placements of its Pure-Vu® System as part of its initial U.S. market launch targeting early adopter hospitals. The Company also confirmed the strategic expansion of the U.S. sales team with the addition of seasoned medical device sales professionals to support the hospital-focused commercial roll-out of the Pure-Vu® System.

  • Business Wire

    Motus GI to Present at the Ladenburg Thalmann Healthcare Conference

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that Tim Moran, Chief Executive Officer, will present a company overview and update at the Ladenburg Thalmann Healthcare Conference on Tuesday, September 24, 2019 at 10:30 AM ET in New York, NY. A live audio webcast of the presentation will be accessible on the Events page of the Investors section on the Company’s website at www.motusgi.com. Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy.

  • Do Institutions Own Shares In Motus GI Holdings, Inc. (NASDAQ:MOTS)?
    Simply Wall St.

    Do Institutions Own Shares In Motus GI Holdings, Inc. (NASDAQ:MOTS)?

    Every investor in Motus GI Holdings, Inc. (NASDAQ:MOTS) should be aware of the most powerful shareholder groups...

  • If You Had Bought Motus GI Holdings (NASDAQ:MOTS) Stock A Year Ago, You'd Be Sitting On A 68% Loss, Today
    Simply Wall St.

    If You Had Bought Motus GI Holdings (NASDAQ:MOTS) Stock A Year Ago, You'd Be Sitting On A 68% Loss, Today

    Even the best stock pickers will make plenty of bad investments. And there's no doubt that Motus GI Holdings, Inc...

  • Business Wire

    Motus GI Announces Pricing of $20 Million Public Offering of Common Stock

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, today announced the pricing of its underwritten registered public offering of 6,666,667 shares of its common stock, offered at a price to the public of $3.00 per share for expected gross proceeds of $20.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Motus GI has granted the underwriters a 30-day option to purchase up to an additional 1,000,000 shares of its common stock on the same terms and conditions. All of the shares in the offering are being sold by Motus GI.

  • Business Wire

    Motus GI Announces Proposed Public Offering of Common Stock

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, today announced that it has commenced an underwritten public offering of its common stock. All of the shares to be sold in the offering are to be sold by Motus GI. In connection with the offering, Motus GI intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering.

  • Business Wire

    Motus GI Bolsters Commercial and Quality/Regulatory Expertise with Two Key Senior Management Additions

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today the appointments of Steven M. Bosrock as Vice President of Global Marketing & Strategy and George G. Peters as Vice President of Quality & Regulatory Affairs.

  • Business Wire

    Motus GI to Present at the JMP Securities Life Sciences Conference

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that Tim Moran, Chief Executive Officer, will present a company overview and update at the JMP Securities Life Sciences Conference on Wednesday, June 19, 2019 at 10:30 AM ET in New York, NY. A live audio webcast of the presentation will be accessible on the Events page of the Investors section on the Company’s website at www.motusgi.com.

  • Motus GI Receives FDA Clearance to Market Pure-Vu® GEN2
    Business Wire

    Motus GI Receives FDA Clearance to Market Pure-Vu® GEN2

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for the second-generation Pure-Vu® System (“Pure-Vu® GEN2”) to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure.

  • Business Wire

    Motus GI Presents Positive Clinical Results from REDUCE Study Evaluating Pure-Vu® System in Hospitalized Colonoscopy Patients at Digestive Disease Week® 2019

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, today announced it will present positive full clinical results from the Company’s REDUCE (“Reliable Endoscopic Diagnosis Utilizing Cleansing Enhancement”) study evaluating the Pure-Vu® System at Digestive Disease Week® 2019 (“DDW”).

  • Business Wire

    Motus GI to Present at the 20th Annual B. Riley FBR Investor Conference

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that Tim Moran, Chief Executive Officer, will present a company overview and update at the 20th Annual B. Riley FBR Investor Conference on Wednesday, May 22, 2019 at 4:30 PM PT in Beverly Hills, CA. A live audio webcast of the presentation will be accessible on the Events page of the Investors section on the Company’s website at www.motusgi.com.

  • How Much Are Motus GI Holdings, Inc. (NASDAQ:MOTS) Insiders Spending On Buying Shares?
    Simply Wall St.

    How Much Are Motus GI Holdings, Inc. (NASDAQ:MOTS) Insiders Spending On Buying Shares?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Business Wire

    Motus GI Reports First Quarter 2019 Financial Results and Provides Corporate Update

    – Full clinical results of REDUCE Study to be presented at Digestive Disease Week® 2019

  • Business Wire

    Motus GI to Present Clinical Results from REDUCE Study Evaluating the Pure-Vu® System at Digestive Disease Week® 2019

    Motus GI Holdings, Inc. (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that full clinical results from the Company’s REDUCE (“Reliable Endoscopic Diagnosis Utilizing Cleansing Enhancement”) study evaluating the Pure-Vu® System will be presented at Digestive Disease Week® 2019 (“DDW”), being held May 18 - 21, 2019 in San Diego, CA. The data being presented at DDW is embargoed until the time of presentation.

  • Business Wire

    Motus GI Reports Full Year 2018 Financial Results and Provides Business Outlook

    – 2018 marked by strengthening of executive team, expansion of commercial organization, bolstering of clinical and health economic data, and achievement of important regulatory mil

  • Business Wire

    Motus GI Expands Intellectual Property Portfolio with Issuance of New U.S. Patent for the Pure-Vu® System

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that the U.S. Patent and Trademark Office (USPTO) has issued patent No. 10,179,202 titled, “Systems and methods for cleaning body cavities and for endoscopic steering,” which protects the Company’s flagship product, the Pure-Vu® System.

  • Business Wire

    Motus GI to Present at the Oppenheimer 29th Annual Healthcare Conference

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that Tim Moran, Chief Executive Officer, will present a company overview and update at Oppenheimer’s 29th Annual Healthcare Conference on Wednesday, March 20, 2019 at 2:45 PM ET in New York, NY. A live audio webcast of the presentation will be accessible on the Events page of the Investors section on the Company’s website at www.motusgi.com.

  • Business Wire

    Motus GI Announces Publication of Pure-Vu® System Clinical Study Data in Peer-Reviewed Journal of Clinical Gastroenterology

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that its manuscript titled, “An intra-procedural endoscopic cleansing device for achieving adequate colon preparation in poorly prepped patients,” has been published in the peer-reviewed Journal of Clinical Gastroenterology.

  • Business Wire

    Motus GI Announces Publication of Pure-Vu® System Clinical Study Data in Peer-Reviewed Endoscopy Journal

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that its manuscript titled, “A novel device for intra-colonoscopy cleansing of inadequately prepared colonoscopy patients – a feasibility study,” has been published in the peer-reviewed journal, Endoscopy.

  • Business Wire

    Motus GI to Present at Biotech Showcase™ 2019

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, today announced that Tim Moran, Chief Executive Officer, will present a company overview and update at Biotech Showcase™ on Tuesday, January 8, 2019 at 4:00 PM PST in San Francisco, CA. In addition to the presentation, management will also be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. A live audio webcast of the presentation will be accessible on the Events page of the Investor section on the Company’s website at www.motusgi.com.